Year: 2023

Munich, Germany , Nov. 06, 2023 (GLOBE NEWSWIRE) — TASKING’s system-level verification and debugging tools now support the Andes RISC-V ISO 26262 certified Processor IPs and associated MachineWare Virtual Models. This collaboration equips SoC design teams with automotive-grade RISC-V IPs and the appropriate tools for early firmware and MCAL (Microcontroller Abstraction Layer) development. TASKING has been serving the global automotive industry for more than 30 years with software development tools certified for functional safety and cybersecurity. The toolset released as part of the collaboration provides the capabilities for multi-core, multi-hart, verification, debugging, performance tuning, timing, and coverage analysis. The toolset can be used with Andes RISC-V development boards and MachineWare high-performance virtual prototyping...

WISeKey’s Subsidiary, SEALSQ Will Be Showcasing a Unique Integrated Solution for Matter Smart Home Devices at the Connectivity Standards Alliance (CSA) Member Meeting, to be held from November 13 – 16 in Geneva Geneva, Switzerland – November 6, 2023: WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), leader in cybersecurity, digital identity, and Internet of Things (IoT) solutions operating as a holding company, today announced that SEALSQ Corp (Nasdaq: LAES) (“SEALSQ”), its semiconductors subsidiary, will be showcasing a unique integrated hardware and PKI service offering for Internet of Things (IoT) devices adopting the Matter standard at the next Alliance Member Meeting in Geneva, scheduled to take place from November 13 – 16, 2023. At the Meeting, SEALSQ will be showcasing its latest secure element,...

NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONNOVEMBER 6, 2023, 1:00 AM ET / 7:00 CET              MDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share Consolidation IRVINE, CA, and HERSTAL, BELGIUM – November 6, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostics company, today announces that the extraordinary general shareholders’ meeting of the Company that was held on November 3, 2023 (“EGM”) approved the proposed transition from a dual listing of the Company’s American Depositary Shares (the “ADSs”) on Nasdaq and ordinary shares (the “Shares”) on Euronext Brussels to a sole listing of Shares...

On November 3, 2023, the subsidiary of Hepsor AS, Hepsor VT49 OÜ, acquired two properties located at the following addresses: Harju County, Rae Parish, Peetri Village, Kodu tee 9a, and Harju County, Rae Parish, Peetri Village, Vana-Tartu mnt 49. The purchased properties have detailed planning in place, allowing for the construction of a commercial building with a rentable area of 4,500 square meters. Hepsor’s total portfolio was 169,300 square meters before the acquisition, of which the commercial real estate portfolio accounted for half, or 85,000 square meters. In Estonian developments, there were 21,000 square meters of commercial property, and in Latvian developments, the figure stood at 63,000 square meters. The newly acquired properties and the planned commercial building are a valuable addition to Hepsor’s Estonian commercial...

UPPSALA, Sweden, Nov. 06, 2023 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that Novogene Asia Pacific Middle East and Africa (AMEA) has adopted the Olink Explore HT platform to deliver advanced next-generation proteomics technology to the scientific community in the region. Novogene is a leading provider of genomic services and solutions offering extensive next generation sequencing (NGS) capacity and bioinformatics expertise. The addition of Olink Explore HT significantly increases Novogene AMEA’s capabilities and quality of multi-omics research services offerings. Olink Explore HT represents the state of the art in next generation proteomics, allowing scientists to accurately measure over 5,400 proteins using only 2µl of sample. By combining Olink PEA technology with an NGS readout...

PF-06954522 was introduced into Pfizer’s Internal Medicine focused clinical pipeline as part of its Q3 2023 results presentationTokyo, Japan and Cambridge, UK, 06 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) has been notified by Pfizer that it has entered a new oral small molecule GLP-1 receptor agonist into a Phase 1 clinical trial. PF-06954522 was discovered by Pfizer scientists during a multi-target research collaboration in which Pfizer had access to Sosei Heptares’ proprietary StaR® (stabilized receptor) technology. Pfizer recently detailed the entry of PF-06954522 into its Internal Medicine focused clinical pipeline as part of its Q3 2023 results on 31 October 2023. Dr. Matt Barnes, President of Heptares Therapeutics and Head of UK R&D, commented: “We are delighted to see the progression...

– Response observed as early as week 1 and durable for up to 16 weeks –– Data support important role for mast cells in the pathogenesis of PN and potentially other chronic itch indications –– Phase 2 PN study to initiate in early 2024 –– Conference call to be held on Monday, November 6th at 8:00 am ET to discuss study results – HAMPTON, N.J., Nov. 05, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from the Company’s Phase 1b study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. Mast cells are believed to play an important...

LUXEMBOURG, Nov. 05, 2023 (GLOBE NEWSWIRE) — Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) (“Tenaris”) announced today that pursuant to its Share Buyback Program (the “Program”) announced on November 1, 2023, covering up to $1.2 billion to be executed in the open market with the intent to cancel the ordinary shares acquired through the Program, Tenaris has entered into a non-discretionary buyback agreement with a primary financial institution (the “Bank”). The Bank will make its trading decisions concerning the timing of the purchases of Tenaris’s ordinary shares independently of and uninfluenced by Tenaris and will act in compliance with applicable rules and regulations, including the Market Abuse Regulation 596/2014 and the Commission Delegated Regulation (EU) 2016/1052 (the “Regulations”). Under the buyback agreement,...

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritisFirst placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody® to report positive topline results in support of potential best-in-class profile Primary endpoint ACR50 met with up to 47% (p